EORTC – European Organisation for Research and Treatment of Cancer shared a post on LinkedIn:
“EORTC has activated the first site of the RENALUT clinical trial, marking the official start of this Phase II study evaluating [177Lu]Lu‑PSMA‑617 (Pluvicto) in metastatic clear cell renal cell carcinoma (ccRCC).
The trial will explore whether 177Lu-PSMA-617, already established in metastatic prostate cancer, could offer a new treatment option for ccRCC patients who have progressed after one or two prior systemic therapies, a group with limited alternatives.
RENALUT will involve 11 centres across Europe and is led by the EORTC Genito‑Urinary Cancer Group (GUCG) in collaboration with international partners.
Read the full announcement.”
Other articles featuring EORTC on OncoDaily.